Management of acute anemia in a Jehovah's Witness patient with acute lymphoblastic leukemia with polymerized bovine hemoglobin-based oxygen carrier: A case report and review of literature

Transfusion

Volumn 50, Issue 7, 2010, Pages 1561-1567

  Donahue, Laura L ^a,b,c   Shapira, Iuliana ^a,b,c   Shander, Aryeh ^a,b,c   Kolitz, Jonathan ^a,b,c   Allen, Steven ^a,b,c   Greenburg, Gerson ^a,b,c  

^a DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CEFEPIME; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DEXAMETHASONE; POLYMERIZED HEMOGLOBIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 11; VINCRISTINE; VORICONAZOLE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; JEHOVAH'S WITNESS; PHYSICAL EXAMINATION; TREATMENT REFUSAL;

ACUTE DISEASE; ADULT; ANEMIA; BLOOD SUBSTITUTES; FEMALE; HEMOGLOBINS; HUMANS; JEHOVAH'S WITNESSES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 77954340283     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2010.02603.x     Document Type: Article

References (43)

1. Kocian R, Spahn DR. Haemoglobin, oxygen carriers and perioperative organ perfusion. Best Pract Res Clin Anaesthesiol 2008 22 : 63 80.
2. Smith J, Bricker S, Putnam B. Tissue oxygen saturation predicts the need for early blood transfusion in trauma patients. Am Surg 2008 74 : 1006 11.
3. Munoz M, Garcia-Erce JA, Villar I, Thomas D. Blood conservation strategies in major orthopaedic surgery: efficacy, safety and European regulations. Vox Sang 2009 96 : 1 13.
4. Carless PA, Henry DA, Moxey AJ, O'connell DL, Brown T, Fergusson DA. Cell salvage for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2006 18 : 1888 98.
5. Goodnough LT, Shander A, Spence R. Bloodless medicine: clinical care without allogeneic blood transfusion. Transfusion 2003 43 : 668 76.
6. Larson RA, Dodge RK, Burns CP, Lee EJ, Stone RM, Schulman P, Duggan D, Davey FR, Sobol RE, Frankel SR, Hooberman AL, Westbrook CA, Arthur DC, George SL, Bloomfield CD, Schiffer CA. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood 1995 85 : 2025 37.
7. Weiser MA, O'Brien S, Thomas DA, Pierce SA, Lam TP, Kantarjian HM. Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimen. Cancer 2002 94 : 285 91.
8. Dorner AJ, Goldman SJ, Keith JC Jr. Interleukin-11. BioDrugs 1997 8 : 418 29.
9. Henry DA, Carless PA, Moxey AJ, Carless PA, O'Connell D, McClelland B, Henderson KM, Sly K, Laupacis A, Fergusson D. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2007 17 : 1886 9.
10. Javidroozi M, Moskowitz DM, Shander A. Adjusting surgical bleeding for dilutional effect of Hextend. Transfusion 2008 48 : 2480 1.
11. Moskowitz DM, Shander A, Javidroozi M, Klein JJ, Perelman SI, Nemeth J, Ergin MA. Postoperative blood loss and transfusion associated with use of Hextend in cardiac surgery patients at a blood conservation center. Transfusion 2008 48 : 768 75.
12. Marinaro J, Smith J, Tawil I, Billstrand M, Crookston KP. HBOC-201 use in traumatic brain injury: case report and review of literature. Transfusion 2009 49 : 2054 9.
13. Spears F, Banerjee A. Hemoglobin M variant and congenital methemoglobinemia: methylene blue will not be effective in the presence of hemoglobin M. Can J Anaesth 2008 55 : 391 2.
14. Bradberry SM. Occupational methaemoglobinaemia. Mechanisms of production, features, diagnosis and management including the use of methylene blue. Toxicol Rev 2003 22 : 13 27.
15. Richards S, Burrett J, Hann I, Chessells J, Hill F, Bailey C. Improved survival with early intensification: combined results from the Medical Research Council childhood ALL randomised trials, UKALL X and UKALL XI. Medical Research Council Working Party on Childhood Leukaemia. Leukemia 1998 12 : 1031 6.
16. Larson RA, Dodge RK, Linker CA, Stone RM, Powell BL, Lee EJ, Schulman P, Davey FR, Frankel SR, Bloomfield CD, George SL, Schiffer CA. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood 1998 92 : 1556 64.
17. Wetzler M, Sanford BL, Kurtzberg J, Deoliveira D, Frankel SR, Powell BL, Kolitz JE, Bloomfield CD, Larson RA. Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: cancer and Leukemia Group B Study 9511. Blood 2007 109 : 4164 7.
18. Rizzo JD, Somerfield MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennett CL. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guidelines. J Clin Oncol 2008 26 : 132 49.
19. Whitaker BI, King MR, Leibeg LL, Schlumpf KS, Schreiber GB. The 2007 nationwide blood collection and utilization survey report.
20. Yearbook of Jehovah's Witnesses 2009.
21. Laszlo D, Agazzi A, Goldhirsch A, Cinieri S, Bertolini F, Rabascio C, Pruneri G, Calabrese L, Cocquio A, Martinelli G. Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: unjustified reluctance to treat. Eur J Haematol 2004 72 : 264 7.
22. Cullis JO, Duncombe AS, Dudley JM, Lumley HS, Apperley JF, Smith AG. Acute leukaemia in Jehovah's Witnesses. Br J Haematol 1998 100 : 664 8.
23. Viele MK, Weiskopf RB. What can we learn about the need for transfusion from patients who refuse blood? The experience with Jehovah's Witnesses. Transfusion 1994 34 : 396 401.
24. Kitchens CS. Are transfusions overrated? Surgical outcome of Jehovah's Witnesses. Am J Med 1993 94 : 117 9.
25. Mann MC, Votto J, Kambe J, McNamee MJ. Management of the severely anemic patient who refuses transfusion: lessons learned during the care of a Jehovah's Witness. Ann Intern Med 1992 117 : 1042 8.
26. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999 91 : 1616 34.
27. Estep T, Bucci E, Farmer M, Greenburg G, Harrington J, Kim HW, Klein H, Mitchell P, Nemo G, Olsen K, Palmer A, Valeri CR, Winslow R. Basic science focus on blood substitutes: a summary of the NHLBI Division of Blood Diseases and Resources Working Group Workshop, March 1, 2006. Transfusion 2008 48 : 776 82.
28. Jahr JS, Lurie F, Bezdikian V, Driessen B, Gunther RA. Measuring circulating blood volume using infused hemoglobin-based oxygen carrier (oxyglobin) as an indicator: verification in a canine hypovolemia model. Am J Ther 2008 15 : 98 101.
29. Jahr JS, Mackenzie C, Pearce LB, Pitman A, Greenburg AG. HBOC-201 as an alternative to blood transfusion: efficacy and safety evaluation in a multicenter phase III trial in elective orthopedic surgery. J Trauma 2008 64 : 1484 97.
30. Jahr JS, Moallempour M, Lim JC. HBOC-201, hemoglobin glutamer-250 (bovine), Hemopure (Biopure Corporation). Expert Opin Biol Ther 2008 8 : 1425 33.
31. Pearce LB, Gawryl MS, Rentko VT, Moon-Massat PF, Rausch CW. HBOC-201 [Hemoglobin Glutamer-250 (bovine), Hemopure]: clinical studies. In : Winslow R, editor. Blood substitutes.
32. Klein HG. Blood substitutes: how close to a solution? Dev Biol (Basel) 2005 120 : 45 52.
33. Moore EE, Johnson JL, Moore FA, Moore HB. The USA Multicenter Prehosptial Hemoglobin-based Oxygen Carrier Resuscitation Trial: scientific rationale, study design, and results. Crit Care Clin 2009 25 : 325 56. Table of Contents.
34. Bolz SS, Vogel L, Sollinger D, Derwand R, de Wit C, Loirand G, Pohl U. Nitric oxide-induced decrease in calcium sensitivity of resistance arteries is attributable to activation of the myosin light chain phosphatase and antagonized by the RhoA/Rho kinase pathway. Circulation 2003 107 : 3081 7.
35. Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA 2005 293 : 1653 62.
36. Dorman SC, Kenny CF, Miller L, Hirsch RE, Harrington JP. Role of redox potential of hemoglobin-based oxygen carriers on methemoglobin reduction by plasma components. Artif Cells Blood Substit Immobil Biotechnol 2002 30 : 39 51.
37. Yu B, Raher MJ, Volpato GP, Bloch KD, Ichinose F, Zapol WM. Inhaled nitric oxide enables artificial blood transfusion without hypertension. Circulation 2008 117 : 1982 90.
38. Stefan DC, Uys R, Wessels G. Hemopure transfusion in a child with severe anemia. Pediatr Hematol Oncol 2007 24 : 269 73.
39. Gannon CJ, Napolitano LM. Severe anemia after gastrointestinal hemorrhage in a Jehovah's Witness: new treatment strategies. Crit Care Med 2002 30 : 1893 5.
40. Agrawal YP, Freedman M, Szczepiorkowski ZM. Long-term transfusion of polymerized bovine hemoglobin in a Jehovah's Witness following chemotherapy for myeloid leukemia: a case report. Transfusion 2005 45 : 1735 8.
41. Pachinburavan MM. Bovine blood and neuromuscular paralysis as bridge to recovery in a patient with severe autoimmune hemolytic anemia. Clin Transl Sci 2009 1 : 172 3.
42. Niquille M, Touzet M, Leblanc I, Baron JF. Reversal of intraoperative myocardial ischemia with a hemoglobin-based oxygen carrier. Anesthesiology 2000 92 : 882 5.
43. Sprung J, Popp H, O'Hara P, Woletz J. The successful use of hemoglobin-based oxygen carrier as a primary blood substitute during abdominal aneurysm repair with large blood loss. Anesth Analg 2001 92 : 1413 5.